Table 2 Clinical characteristics of... | American Society of Hematology

Table 2

Clinical characteristics of patients from the retrospective analysis of reports of bone marrow reticulin in romiplostim clinical trials

Patient ID	Age, y/sex	Duration of ITP, y	Splenectomy	No. of ITP treatments before romiplostim	Maximum dose of romiplostim, μg/kg	Duration of romiplostim exposure, wk*	Platelet count nearest to bone marrow examination, ×10⁹/L	Maximum platelet count before report of reticulin, ×10⁹/L	Relevant medical history
1	40/M	15	Yes	6	9	5	9	10	Bone marrow hypocellularity; chromosomal abnormality (inversion 12)
2	27/F	12	Yes	8	11	40	15	565	—
3	60/F	23	Yes	8	11	45	25	157	—
4	31/M	2	Yes	3	18	26	33	523	—
5	53/M	7	Yes	9	8	35	86	88	—
6	58/M	6	Yes	8	15	31	58	70	—
7	54/F	3	No†	4	13	27	4	71	Systemic lupus erythematosus
8	37/M	3	Yes	8	9	26	4	221	—
9	63/M	15	No	NA	11	32	47	72	Clonal hematologic disorder (20q deletion)
10	44/F	8	Yes	4	5	123	82	728	—

Patient ID	Age, y/sex	Duration of ITP, y	Splenectomy	No. of ITP treatments before romiplostim	Maximum dose of romiplostim, μg/kg	Duration of romiplostim exposure, wk*	Platelet count nearest to bone marrow examination, ×10⁹/L	Maximum platelet count before report of reticulin, ×10⁹/L	Relevant medical history
1	40/M	15	Yes	6	9	5	9	10	Bone marrow hypocellularity; chromosomal abnormality (inversion 12)
2	27/F	12	Yes	8	11	40	15	565	—
3	60/F	23	Yes	8	11	45	25	157	—
4	31/M	2	Yes	3	18	26	33	523	—
5	53/M	7	Yes	9	8	35	86	88	—
6	58/M	6	Yes	8	15	31	58	70	—
7	54/F	3	No†	4	13	27	4	71	Systemic lupus erythematosus
8	37/M	3	Yes	8	9	26	4	221	—
9	63/M	15	No	NA	11	32	47	72	Clonal hematologic disorder (20q deletion)
10	44/F	8	Yes	4	5	123	82	728	—

NA indicates not available; and —, not applicable.

Exposure to romiplostim until the time of the first follow-up biopsy.

Patient underwent a splenectomy approximately 1 week after the reticulin-positive biopsy.